Patents by Inventor Weicai XUE

Weicai XUE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2,4-bis(nitrogen-containing group)-substituted pyrimidine compound, preparation method and use thereof
    Patent number: 11267802
    Abstract: Provided are a 2, 4-di-(nitrogen containing group) substituted pyrimidine compound represented by a general formula (I), a pharmaceutically acceptable salt and a stereoisomer thereof, a preparation method thereof, and a use thereof in preparation of anti-tumor drugs. The compound having a structural feature shown in the general formula (I) can selectively suppress activity of mutant epidermal growth factor receptors (EGFR), including single-mutant EGFR (T790M) and double-mutant EGFR (including L858R/T790M and ex19del/T790M), and can suppress activity of single gain-of-function mutant EGFR (including L858R and ex19del) as well. The compound has a weak suppression effect on wild-type EFGR and a very high selectivity, and thus it has a potential to be used in preparation of drugs for treating EGFR mutant tumors, especially non-small cell lung cancer (NSCLC) comprising a T790M EGFR mutation.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: March 8, 2022
    Assignee: BEBETTER MED INC.
    Inventors: Xiong Cai, Changgeng Qian, Yunwo Weng, Bin Liu, Yanyan Wang, Mingsheng Lin, Junqi Li, Yuanhui Qing, Huajin You, Shiqing Zhou, Weicai Xue
  • 2,4-BIS(NITROGEN-CONTAINING GROUP)-SUBSTITUTED PYRIMIDINE COMPOUND, PREPARATION METHOD AND USE THEREOF
    Publication number: 20200331891
    Abstract: Provided are a 2, 4-di-(nitrogen containing group) substituted pyrimidine compound represented by a general formula (I), a pharmaceutically acceptable salt and a stereoisomer thereof, a preparation method thereof, and a use thereof in preparation of anti-tumor drugs. The compound having a structural feature shown in the general formula (I) can selectively suppress activity of mutant epidermal growth factor receptors (EGFR), including single-mutant EGFR (T790M) and double-mutant EGFR (including L858R/T790M and ex19del/T790M), and can suppress activity of single gain-of-function mutant EGFR (including L858R and ex19del) as well. The compound has a weak suppression effect on wild-type EFGR and a very high selectivity, and thus it has a potential to be used in preparation of drugs for treating EGFR mutant tumors, especially non-small cell lung cancer (NSCLC) comprising a T790M EGFR mutation.
    Type: Application
    Filed: July 26, 2016
    Publication date: October 22, 2020
    Applicant: GUANGZHOU BEBETTER MEDICINE TECHNOLOGY CO., LTD.
    Inventors: Xiong CAI, Changgeng QIAN, Yunwo WENG, Bin LIU, Yanyan WANG, Mingsheng LIN, Junqi LI, Yuanhui QING, Huajin YOU, Shiqing ZHOU, Weicai XUE
  • 2,4-BIS(NITROGEN-CONTAINING GROUP)-SUBSTITUTED PYRIMIDINE COMPOUND, PREPARATION METHOD AND USE THEREOF
    Publication number: 20200165227
    Abstract: Provided are a 2, 4-di-(nitrogen containing group) substituted pyrimidine compound represented by a general formula (I), a pharmaceutically acceptable salt and a stereoisomer thereof, a preparation method thereof, and a use thereof in preparation of anti-tumor drugs. The compound having a structural feature shown in the general formula (I) can selectively suppress activity of mutant epidermal growth factor receptors (EGFR), including single-mutant EGFR (T790M) and double-mutant EGFR (including L858R/T790M and ex19del/T790M), and can suppress activity of single gain-of-function mutant EGFR (including L858R and ex19del) as well. The compound has a weak suppression effect on wild-type EFGR and a very high selectivity, and thus it has a potential to be used in preparation of drugs for treating EGFR mutant tumors, especially non-small cell lung cancer (NSCLC) comprising a T790M EGFR mutation.
    Type: Application
    Filed: July 26, 2016
    Publication date: May 28, 2020
    Applicant: GUANGZHOU BEBETTER MEDICINE TECHNOLOGY CO., LTD.
    Inventors: Xiong CAI, Changgeng QIAN, Yunwo WENG, Bin LIU, Yanyan WANG, Mingsheng LIN, Junqi LI, Yuanhui QING, Huajin YOU, Shiqing ZHOU, Weicai XUE
  • Pyrimidine or pyridopyridone compound and application thereof
    Patent number: 10183941
    Abstract: The present invention discloses a pyrimidine or pyridopyridone compound as shown in formula (I) and an application thereof relating to the technical field of medicament preparation. The compound can selectively suppress cyclin-dependent kinases (Cdks) CDK4 and CDK6 with almost no suppression of the activity of the kinase CDK2. Thus, the compound can be used for various diseases caused by cell cycle control disorders involving CDK4 and CDK6, and particularly in the treatment of malignant tumors.
    Type: Grant
    Filed: May 31, 2016
    Date of Patent: January 22, 2019
    Assignee: GUANGZHOU BEBETTER MEDICINE TECHNOLOGY CO., LTD.
    Inventors: Xiong Cai, Changgeng Qian, Junqi Li, Yuanhui Qing, Yanyan Wang, Weicai Xue, Huajin You
  • PYRIMIDINE OR PYRIDOPYRIDONE COMPOUND AND APPLICATION THEREOF
    Publication number: 20180297995
    Abstract: The present invention discloses a pyrimidine or pyridopyridone compound as shown in formula (I) and an application thereof relating to the technical field of medicament preparation. The compound can selectively suppress cyclin-dependent kinases (Cdks) CDK4 and CDK6 with almost no suppression of the activity of the kinase CDK2. Thus, the compound can be used for various diseases caused by cell cycle control disorders involving CDK4 and CDK6, and particularly in the treatment of malignant tumors.
    Type: Application
    Filed: May 31, 2016
    Publication date: October 18, 2018
    Applicant: GUANGZHOU BEBETTER MEDICINE TECHNOLOGY CO., LTD.
    Inventors: Xiong CAI, Changgeng QIAN, Junqi LI, Yuanhui QING, Yanyan WANG, Weicai XUE, Huajin YOU